From Analysis:
The abstract focuses exclusively on amyloid plaque reduction, leaving unknown whether this pathway addresses tau tangles, neuroinflammation, or synaptic loss. Since AD is multifactorial, understanding the full therapeutic scope is essential for clinical translation. Gap type: open_question Source paper: Peripheral cancer attenuates amyloid pathology in Alzheimer's disease via cystatin-c activation of TREM2. (2026, Cell, PMID:41576952)
These hypotheses emerged from the same multi-agent debate that produced this hypothesis.
Cancer/cystatin-C-mediated amyloid reduction decreases amyloid-nucleated tau pathology through reduced BACE1 activity and GSK3β activation. This hypothesis is almost certainly true but uninformative—it re-explains known downstream biology rather than identifying a novel mechanism. Should be demoted from 'mechanism' to 'expected downstream consequence of amyloid lowering.'
No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["APP Substrate
Amyloid Precursor Protein"]
B["BACE1 Cleavage
beta-Secretase Activity"]
C["Amyloid-beta Oligomers
Neurotoxic Aggregates"]
D["GSK3beta Activation
Kinase Dysregulation"]
E["Tau Hyperphosphorylation
AT180 and PHF-1 Epitopes"]
F["Neurofibrillary Tangles
Tau Aggregation Pathology"]
G["BACE1 Inhibition or
Amyloid Lowering Strategy"]
H["GSK3beta Suppression
Indirect via Reduced Abeta"]
I["Tau Pathology Reduction
Secondary Therapeutic Effect"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.->|"inhibits"| B
G --> H
H -.->|"reduces"| D
H --> I
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784
style I fill:#1b5e20,stroke:#81c784,color:#81c784
Title: Cystatin-C-activated TREM2 microglia reduce tau pathology through enhanced phagocytosis of extracellular tau seeds
Mechanism: TREM2 activation by cystatin C promotes a disease-associated microglia (DAM) phenotype with enhanced phagocytic capacity. Activated microglia may ingest and clear extracellular tau oligomers and seeds, preventing template-dependent propagation of tau tangles.
Target: TREM2 signaling axis (Syk → PLCγ2),
Before evaluating individual hypotheses, several systemic issues constrain confidence across all seven proposals:
1. Causal vs. Correlative Ambiguity
The source paper establishes a correlation between peripheral cancer, elevated cystatin C, and reduced amyloid burden. All seven hypotheses require demonstrating that cystatin C is both necessary and sufficient for non-amyloid effects—a causation that has not been established even for the amyloid phenotype.
**2. Blood
The key feasibility filter is the source paper itself. In the February 5, 2026 `Cell` paper, Li et al. report that peripheral cancer/CSPs reduced amyloid in `5xFAD` and `APP/PS1`, but “did not affect tau protein misfolding in the `rTg4510` mice,” which sharply limits any claim of a broad anti-tau effect beyond amyloid-linked contexts. Separately, the March 5, 2026 phase 2 `AL002` TREM2 agonist trial showed CNS target engagement but missed its clinical primary endpoint in early AD, so the translational bar for any TREM2-based program is now much higher. Sources: `Cell` paper abstract/PDF and `N
{"ranked_hypotheses":[{"title":"Anti-inflammatory microglial reprogramming via cystatin-C/TREM2 axis","description":"Systemic tumors secrete cystatin C which crosses the BBB via LRP1 and engages TREM2 on microglia, shifting neuroinflammatory profile from pro-inflammatory (IL-1β, TNF-α, IL-6) to anti-inflammatory/regulatory (IL-10, TGF-β). This represents the most druggable pharmacology story, though the field's first major TREM2 agonist phase 2 (AL002) missed its clinical primary endpoint despite biomarker engagement. Clinical translation requires biomarker-enriched populations and likely comb
No clinical trials data available
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
No knowledge graph edges recorded
neurodegeneration | 2026-04-25 | completed
No comments yet. Be the first to comment!